Nublexa Tablet contains Regorafenib 40 mg, a multi-kinase inhibitor used in the treatment of various malignancies. Regorafenib exerts its therapeutic effect by inhibiting multiple protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment, thereby reducing tumor growth and proliferation. Nublexa is primarily indicated for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma in patients who have previously received standard therapies. The recommended dosage and administration should be determined by a healthcare professional based on the patient’s condition and tolerance. Common adverse effects associated with Regorafenib include hypertension, hand-foot skin reaction, fatigue, diarrhea, and hepatotoxicity; therefore, regular monitoring of blood pressure, liver function tests, and other relevant parameters is essential during therapy. Patients should be advised to report any unusual symptoms promptly. Nublexa should be used with caution in individuals with pre-existing liver impairment or cardiovascular conditions. It is contraindicated in pregnancy due to potential teratogenic effects. As with all anticancer agents, adherence to prescribed dosing schedules and close clinical supervision are critical to optimize therapeutic outcomes and minimize adverse effects.